Last reviewed · How we verify
NCT06362226
Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management
Phase 1 trial testing Steroid/Antibiotic (Maxitrol) in Periorbital Burns. Withdrawn.
5 June 2026
Quick facts
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 5 June 2026 |
| Primary completion | 5 June 2026 |
| Estimated completion | 5 June 2026 |
Drugs / interventions tested
- Steroid/Antibiotic (Maxitrol) — full drug profile →
- 5-FU/Kenalog — full drug profile →
Conditions studied
- Periorbital Burns — all drugs for Periorbital Burns →
Sponsor
Virginia Commonwealth University
Who can join
18 and older, any sex, with Periorbital Burns. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Comparison of wound healing time
Time frame: 12 months
This outcome is comparing the would healing time between the 2 groups. A shorter would healing time would indicate faster recovery. -
Comparison of infection rate
Time frame: 12 months
This outcome is comparing the infection rate during treatment. A lower infection rate may indicate which treatment is superior to the other. -
Comparison of complication rates
Time frame: 12 months
Complication rate is assessed through the occurrence of adverse events. A lower complication rate could indicate improved safety and tolerability over one treatment.
Sponsor's own description
The purpose of this study is to evaluate the effectiveness in using subcutaneous 5-FU/Kenalog \& topical Maxitrol Ophthalmic ointment as different therapeutic adjuncts in the prevention of pathologic remodeling after periorbital burns.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06362226
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Virginia Commonwealth University trials
Trials by the same sponsor.
- NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
- NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
- NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06362226 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
- Last refreshed: 5 June 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362226.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing